Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Related Citations for PubMed (Select 23016780)

1.

Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe?

Tomljenovic L, Spinosa JP, Shaw CA.

Curr Pharm Des. 2013;19(8):1466-87. Review.

PMID:
23016780
2.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

3.

Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.

Pomfret TC, Gagnon JM Jr, Gilchrist AT.

J Clin Pharm Ther. 2011 Feb;36(1):1-9. doi: 10.1111/j.1365-2710.2009.01150.x. Review.

PMID:
21198715
4.

Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.

Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.

Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280. Review.

PMID:
21361739
5.

Human papillomavirus vaccine: widening the scope for cancer prevention.

No JH, Kim MK, Jeon YT, Kim YB, Song YS.

Mol Carcinog. 2011 Apr;50(4):244-53. doi: 10.1002/mc.20657. Review.

PMID:
21465574
6.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

7.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

8.

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE.

J Natl Cancer Inst. 2009 Apr 1;101(7):475-87. doi: 10.1093/jnci/djn510. Epub 2009 Mar 24.

9.

Cervical cancers after human papillomavirus vaccination.

Beller U, Abu-Rustum NR.

Obstet Gynecol. 2009 Feb;113(2 Pt 2):550-2. doi: 10.1097/AOG.0b013e318191a54a.

PMID:
19155953
10.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

11.

[What should be known for the introduction of an HPV vaccine?].

Muñoz N, Jacquard AC.

Presse Med. 2008 Oct;37(10):1377-90. doi: 10.1016/j.lpm.2008.04.008. Epub 2008 Sep 10. Review. French.

PMID:
18786806
12.

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.

Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.

PMID:
19493565
13.

Post-licensure monitoring of HPV vaccine in the United States.

Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF.

Vaccine. 2010 Jul 5;28(30):4731-7. doi: 10.1016/j.vaccine.2010.02.019. Epub 2010 Feb 25. Review.

PMID:
20188681
14.

Human papillomavirus vaccines.

Satyaprakash A, Creed R, Ravanfar P, Mendoza N.

Dermatol Ther. 2009 Mar-Apr;22(2):150-7. doi: 10.1111/j.1529-8019.2009.01227.x. Review.

PMID:
19335726
15.

HPV vaccine: Cervarix.

Szarewski A.

Expert Opin Biol Ther. 2010 Mar;10(3):477-87. doi: 10.1517/14712591003601944. Review.

PMID:
20132062
16.

Currently approved prophylactic HPV vaccines.

Harper DM.

Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123. Review.

PMID:
19943762
17.

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

Capri S, Gasparini R, Panatto D, Demarteau N.

Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19.

PMID:
21334734
18.

Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.

McIntosh J, Sturpe DA, Khanna N.

J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):e1-13; quiz e14-7. doi: 10.1331/JAPhA/2008.07032. Review.

PMID:
18192123
19.

Introducing human papillomavirus vaccines - questions remain.

Paavonen J, Lehtinen M.

Ann Med. 2008;40(3):162-6. doi: 10.1080/07853890701802404. Review.

PMID:
18382882
20.

Worldwide impact of the human papillomavirus vaccine.

Hakim AA, Dinh TA.

Curr Treat Options Oncol. 2009 Apr;10(1-2):44-53. doi: 10.1007/s11864-009-0094-4. Epub 2009 Apr 23. Review.

PMID:
19387841
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk